Preclinical WebsiteClinical Website

Model Overview

Experimental Autoimmune Encephalomyelitis (EAE) is a gold-standard model for assessing therapeutic agents targeting autoimmune-mediated disease. EAE is most commonly induced by immunizing animals against myelin-derived antigens, such as:

  • Myelin Oligodendrocyte Glycoprotein (MOG35-55 or MOG1-125)
  • Myelin Basic Protein (MBP)
  • Proteolipid Protein (PLP)

EAE models several aspects of human MS. It is a model of T cell-mediated autoimmune disease with the following key pathologic features:

  • Neuroinflammation
  • Peripheral inflammatory infiltrates
  • Demyelination
  • Axonal damage

EAE is characterized by a progressive paralysis followed by full or partial recovery, which may then be relapsing-remitting or chronic depending on the specific model.

Model Generation

  • We most frequently use the MOG35-55 model in C57BL/6 mice, which is a well-established, chronic model that is advantageous for therapeutic studies
  • Injection of MOG35-55 peptide with Complete Freund's Adjuvant (CFA) and pertussis toxin on a defined schedule

Our Validated Measures

  • Body weight
  • EAE scoring
  • Grip strength test & wire hang test
  • Neurofilament Light (NfL) measures in plasma & CSF
  • Immunohistochemistry & multiplex immunofluorescence of the spinal cord

Learn more about our characterization of this model and our validated measures.

Discover more of our Multiple Sclerosis Models

FAQs

What is the "EAE Score"?

The EAE Score is a standardized. clinical scoring system that assesses the disease progression in this model. It typically uses a 5 point scale. An example is:

MS

There are several variations on the EAE score, and we would be happy to discuss what may be most suitable for your study.


What is the typical dosing paradigm?

The dosing paradigm can be:
(1) Prophylactic (starting before or at the time of immunization)
(2) Therapeutic/interventional
      (a) Starting when the first mice show symptoms
      (b) Starting from the first signs of symptoms in each mouse
      (c) Starting a fixed time after immunization or symptom onset in each mouse

Our team can discuss the best dosing paradigm for your study.


Can a "positive control" be included in the study?

Yes. The existence of well-established positive controls is an advantage of the EAE models.


What is the difference between using MOG35-55 and MOG1-125?

The MOG1-125 induced model is thought to have some dependence on B cells, which may be useful for evaluating B cell-targeted therapies.


What is the difference between active and passive EAE models?

In active EAE, the disease is induced via immunization with myelin-derived antigens, such as MOG, PLP, or MBP. The MOG35-55-induced EAE is commonly used to induce EAE in C57BL/6 mice, making is a well-established and widely employed model for studying autoimmune demyelinating diseases.

In passive EAE (also known as adoptive transfer), the disease is induced by first generating encephalitogenic CD4+ T cells that are specific for myelin-derived antigens in immunized (donor) mice, then activated these cells in culture, and finally injecting them into recipient mice. This approach is useful when therapies target specific T cell populations.


Can Biospective perform "adoptive transfer" (passive) EAE model studies?

Yes. We can generate these models and our EAE model scientists would be happy to discuss further with you.


Is neurofilament light (NfL) a useful measure in EAE?

Definitely. Plasma and/or CSF NfL levels are excellent measures of axonal damage in this model.


More Information

Let us know what you’re interested in. Our team will be happy to discuss with you!

Email us at i[email protected] or simply complete & submit the form below. 

Name*
Email*
Phone Number*
Affiliation (Company/University)*
Message*

Your privacy is important to us. We will protect your data as outlined in our Privacy Notice.

I agree to the terms in the Privacy Notice*

We use necessary cookies to make our site work. We also use other cookies to help us make improvements by measuring how you use the site or for marketing purposes. You have the choice to accept or reject them all. For more detailed information about the cookies we use, see our Privacy Notice.